Acrinova AB Series B (ACRI-B) fair value: what the stock is really worth
As of Oct 20, 2026: fair value (intrinsic value) of Acrinova AB Series B stock SEK 18.50, price SEK 6.68, upside +176.9%, quality 63 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range kr 3.46 – kr 10.70 · fair‑value band kr 12.21 – kr 27.33 · the kr 6.68 price screens below the kr 18.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Acrinova AB Series B in your weekly email
Every Wednesday you see whether Acrinova AB Series B is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Acrinova AB (publ), a real estate company, owns, develops, and manages real estate properties in Sweden.
Show moreShow less
Its property portfolio includes trade and service, warehouse and production, and residential properties, as well as logistics/production, housing, shop, industrial and commercial premises, restaurant, and office. The company was incorporated in 2014 and is headquartered in Malmö, Sweden.
Stock analysis
Acrinova AB Series B (ACRI-B) currently trades at kr 6.68, while our model-based Fair Value estimate is kr 18.50, implying the stock looks roughly 63.9% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 74.49 per share, and 13 of the 13 models we run sit above the kr 6.68 price.
Bear case: the Asset-Based group reads lowest at kr 8.36, and 0 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: kr 12.21 (bear) to kr 27.33 (bull), the price of kr 6.68 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Real Estate sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Acrinova AB Series B reported revenue of 128M SEK in FY2025 versus 102M SEK in FY2021, a compound +5.9%/yr. Reported net income was 60.0M SEK in FY2025, compounding −20.9%/yr from FY2021.
Key figures
Market cap 291M SEK (≈ $29.3M) Micro · P/E ratio 11.2 · P/S ratio 4.04 · EPS (TTM) kr 0.5900 · Net margin 50.2% · Return on equity 5.4% · Return on assets (EBIT) 5.4% · Operating margin 32.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 67 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Real Estate peers we cover trades at −50% fair-value upside, at 177%, ACRI-B screens cheaper than that median.
Fair Value models
Bearkr 12.21Fair Value kr 18.50Bullkr 27.33
Price kr 6.68 · Upside +176.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−19.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Start year 2020 (pandemic). Over 10 years: +37.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−6.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−6.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8.6% vs 11.3%, steady
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.58% → 57%
2025 sits 80% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Real Estate - Diversified · 131 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score63 · Top 25%
Fair Value upside+176.9% · Top 25%
Profitability
Return on equity (12 months)5.4% · Above median
Return on assets5.8% · Top 25%
Net margin (12 months)50.2% · Top 25%
Operating margin (12 months)32.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)−68.7% · Bottom 25%
Dividend yield (12 months)56.7% · Top 25%
Balance sheet
Debt / equity0.61× · Above median
Valuation Multiplesvs Real Estate - Diversified median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Acrinova AB Series B Fair Value". https://www.fairvalue-calculator.com/stock/ACRI-B
Frequently asked questions
Is Acrinova AB Series B (ACRI-B) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of kr 18.50 versus a price of kr 6.68, about +177% upside (undervalued).
What is the fair value of ACRI-B?
Our model-based fair value for Acrinova AB Series B is kr 18.50 (as of Oct 3, 2026), built from audited fundamentals. The current price: kr 6.68.
What is the quality score of ACRI-B?
Acrinova AB Series B has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Acrinova AB Series B (ACRI-B)?
Our model-based price target is the fair value of kr 18.50 (as of Oct 3, 2026) from 13 valuation models. Cautious scenario kr 12.21, optimistic scenario kr 27.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Acrinova AB Series B stock forecast for 2026?
Our models put fair value at kr 18.50, about +177% upside versus a price of kr 6.68 (undervalued). Cautious scenario kr 12.21, optimistic scenario kr 27.33. The calculation is refreshed regularly with new filings.
What is the revenue of Acrinova AB Series B (ACRI-B)?
Acrinova AB Series B reported trailing-twelve-month revenue of about 72.1M SEK (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Acrinova AB Series B (ACRI-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Acrinova AB Series B it is kr 18.50 per share (as of Oct 3, 2026), against a price of kr 6.68. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Acrinova AB Series B stock overvalued or undervalued in 2026?
As of Oct 3, 2026, ACRI-B trades below its calculated fair value: price kr 6.68, fair value kr 18.50, a gap of about +177% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACRI-B?
No. The price is what the market pays today (kr 6.68); the fair value is what the company's own numbers justify (kr 18.50). For Acrinova AB Series B the two are kr 11.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Acrinova AB Series B worth?
The market values Acrinova AB Series B at about 291M SEK (market capitalisation, as of Oct 3, 2026). Per share that is kr 6.68; our models calculate a fair value of kr 18.50 per share.
What do the bullish and bearish scenarios say about ACRI-B?
Our models span a range for Acrinova AB Series B: cautious scenario kr 12.21, base kr 18.50, optimistic kr 27.33 per share (as of Oct 3, 2026, price kr 6.68). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ACRI-B?
Acrinova AB Series B trades at a price-to-earnings ratio of 11.2 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 18.50 is built from several models across several years. Other multiples: P/B 0.5, P/S 4.0, EV/EBITDA 26.5.
How solid is the balance sheet of Acrinova AB Series B (ACRI-B)?
Balance-sheet figures for Acrinova AB Series B (as of Oct 3, 2026): return on equity 5.4%, debt of 0.61 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is ACRI-B from its 52-week high?
Acrinova AB Series B trades at kr 6.68, about 38% below its 52-week high of kr 10.70 and 3% above the low of kr 6.50 (as of Oct 20, 2026). Distance from the high says nothing about value: that is what the fair value of kr 18.50 is for.
Which stocks are comparable to Acrinova AB Series B?
From the same area (Real Estate) we also value Swiss Prime Site AG, The Phoenix Mills Limited, Prestige Estates Projects Limited, Umm Al Qura for Development and Construction Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Acrinova AB Series B stock attractive at the current price?
The data as of Oct 3, 2026: price kr 6.68, calculated fair value kr 18.50 (+177%), Quality Score 63/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACRI-B calculated?
We run Acrinova AB Series B through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 18.50, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Acrinova AB Series B currently trades 64 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Acrinova AB Series B (ACRI-B)?
The closing price on Oct 20, 2026 was kr 6.68. Our model-based fair value is kr 18.50, about +177% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Acrinova AB Series B right now?
The price is below even our cautious bear case (kr 12.21). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (kr 12.21 to kr 27.33) leaves room in how you read the outcome.
Key figures of Acrinova AB Series B
How large is the market capitalisation of Acrinova AB Series B (ACRI-B)?
The market capitalisation of Acrinova AB Series B is 291M SEK (≈ $29.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Acrinova AB Series B (ACRI-B)?
The price-to-sales ratio of Acrinova AB Series B is 4.04 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Acrinova AB Series B (ACRI-B)?
Earnings per share at Acrinova AB Series B are kr 0.5900 (price ÷ EPS = P/E 11.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Acrinova AB Series B (ACRI-B)?
The net margin of Acrinova AB Series B is 50.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Acrinova AB Series B (ACRI-B)?
The return on equity (ROE) of Acrinova AB Series B is 5.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Acrinova AB Series B (ACRI-B)?
On an EBIT basis the return on assets of Acrinova AB Series B is 5.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Acrinova AB Series B (ACRI-B)?
The operating margin of Acrinova AB Series B is 32.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Acrinova AB Series B (ACRI-B)?
Revenue at Acrinova AB Series B is growing −68.7% versus a year earlier (3y avg −0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Acrinova AB Series B (ACRI-B)?
Earnings per share at Acrinova AB Series B are growing −94.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Acrinova AB Series B (ACRI-B) generate?
The free cash flow of Acrinova AB Series B is 251M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Acrinova AB Series B (ACRI-B) carry?
The net debt of Acrinova AB Series B is 250M SEK (fiscal year 2025, ≈ 1.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Acrinova AB Series B in the live analysis
One click puts Acrinova AB Series B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 3, 2026